A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Hepatic Steatosis and Elevated Liver Stiffness
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Apr 2018
At a glance
- Drugs GS 0976 (Primary) ; GS 9674 (Primary) ; Selonsertib (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; Proof of concept
- Sponsors Gilead Sciences
- 13 Apr 2018 Results presented in the, Gilead Sciences media release.
- 13 Apr 2018 According to a Gilead Sciences media release, the first 12-Week data of the combination therapy was presented at the The International Liver Congress (2018).
- 06 Feb 2018 Status changed from recruiting to active, no longer recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History